A detailed history of First Bank & Trust transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, First Bank & Trust holds 51,575 shares of GILD stock, worth $4.82 Million. This represents 0.85% of its overall portfolio holdings.

Number of Shares
51,575
Previous 50,005 3.14%
Holding current value
$4.82 Million
Previous $3.43 Million 26.03%
% of portfolio
0.85%
Previous 0.72%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

BUY
$66.59 - $83.99 $104,546 - $131,864
1,570 Added 3.14%
51,575 $4.32 Million
Q2 2024

Jul 09, 2024

BUY
$63.15 - $72.88 $741,128 - $855,319
11,736 Added 30.67%
50,005 $3.43 Million
Q1 2024

Apr 17, 2024

BUY
$71.58 - $87.29 $183,889 - $224,248
2,569 Added 7.2%
38,269 $2.8 Million
Q4 2023

Jan 12, 2024

SELL
$73.27 - $83.09 $88,656 - $100,538
-1,210 Reduced 3.28%
35,700 $2.89 Million
Q3 2023

Oct 11, 2023

SELL
$73.94 - $80.67 $57,007 - $62,196
-771 Reduced 2.05%
36,910 $2.77 Million
Q2 2023

Jul 12, 2023

SELL
$76.01 - $86.7 $295,830 - $337,436
-3,892 Reduced 9.36%
37,681 $2.9 Million
Q1 2023

Apr 25, 2023

SELL
$77.31 - $88.08 $1.65 Million - $1.88 Million
-21,341 Reduced 33.92%
41,573 $3.45 Million
Q4 2022

Jan 27, 2023

BUY
$62.32 - $89.47 $95,848 - $137,604
1,538 Added 2.51%
62,914 $5.4 Million
Q3 2022

Oct 28, 2022

BUY
$59.54 - $68.01 $227,561 - $259,934
3,822 Added 6.64%
61,376 $3.79 Million
Q2 2022

Jul 22, 2022

BUY
$57.72 - $65.01 $455,526 - $513,058
7,892 Added 15.89%
57,554 $3.56 Million
Q1 2022

Apr 29, 2022

BUY
$57.92 - $72.58 $374,452 - $469,229
6,465 Added 14.97%
49,662 $2.95 Million
Q4 2021

Feb 01, 2022

BUY
$64.88 - $73.64 $18,490 - $20,987
285 Added 0.66%
43,197 $3.14 Million
Q3 2021

Oct 18, 2021

BUY
$67.69 - $73.03 $43,321 - $46,739
640 Added 1.51%
42,912 $3 Million
Q2 2021

Aug 10, 2021

BUY
$63.47 - $69.35 $19,041 - $20,805
300 Added 0.71%
42,272 $2.91 Million
Q1 2021

Apr 14, 2021

BUY
$60.0 - $68.46 $206,880 - $236,050
3,448 Added 8.95%
41,972 $2.71 Million
Q4 2020

Jan 27, 2021

BUY
$56.65 - $64.55 $715,829 - $815,653
12,636 Added 48.81%
38,524 $2.25 Million
Q3 2020

Oct 26, 2020

BUY
$62.1 - $78.08 $20,803 - $26,156
335 Added 1.31%
25,888 $1.64 Million
Q2 2020

Aug 05, 2020

SELL
$72.34 - $84.0 $850,356 - $987,420
-11,755 Reduced 31.51%
25,553 $1.97 Million
Q1 2020

Apr 14, 2020

BUY
$62.63 - $80.22 $485,883 - $622,346
7,758 Added 26.25%
37,308 $2.79 Million
Q4 2019

Jan 31, 2020

BUY
$61.62 - $67.78 $103,891 - $114,277
1,686 Added 6.05%
29,550 $1.92 Million
Q3 2019

Oct 17, 2019

BUY
$62.51 - $69.0 $1.66 Million - $1.83 Million
26,519 Added 1971.67%
27,864 $1.77 Million
Q2 2019

Jul 26, 2019

SELL
$61.87 - $69.38 $26,604 - $29,833
-430 Reduced 24.23%
1,345 $91,000
Q1 2019

Apr 15, 2019

SELL
$62.53 - $70.05 $20,072 - $22,486
-321 Reduced 15.31%
1,775 $115,000
Q4 2018

Jan 28, 2019

BUY
$60.54 - $79.0 $4,358 - $5,688
72 Added 3.56%
2,096 $131,000
Q3 2018

Oct 10, 2018

SELL
$71.28 - $78.92 $1,782 - $1,973
-25 Reduced 1.22%
2,024 $154,000
Q2 2018

Jul 31, 2018

BUY
$64.88 - $75.68 $5,709 - $6,659
88 Added 4.49%
2,049 $145,000
Q4 2017

Jan 18, 2018

BUY
$71.15 - $83.52 $8,466 - $9,938
119 Added 6.46%
1,961 $140,000
Q3 2017

Oct 25, 2017

BUY
$72.11 - $85.47 $132,826 - $157,435
1,842
1,842 $149,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $117B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track First Bank & Trust Portfolio

Follow First Bank & Trust and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Bank & Trust, based on Form 13F filings with the SEC.

News

Stay updated on First Bank & Trust with notifications on news.